Premium
Expression patterns of 5‐lipoxygenase in human brain with traumatic injury and astrocytoma
Author(s) -
Zhang Lei,
Zhang WeiPing,
Hu Hua,
Wang MengLing,
Sheng WenWen,
Yao HongTian,
Ding Wei,
Chen Zhong,
Wei ErQing
Publication year - 2006
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/j.1440-1789.2006.00658.x
Subject(s) - human brain , immunohistochemistry , astrocytoma , traumatic brain injury , arachidonate 5 lipoxygenase , neuroprotection , cytosol , lipoxygenase , pathology , biology , medicine , glioma , neuroscience , enzyme , cancer research , arachidonic acid , biochemistry , psychiatry
5‐Lipoxygenase (5‐LOX) is a key enzyme in the metabolism of arachidonic acid to leukotrienes. The levels of leukotrienes increase after brain injury and when tumors are present. It has been reported that 5‐LOX is widely expressed in the brain and that 5‐LOX inhibition provides neuroprotection. However, there is still no information available for the expression patterns of 5‐LOX in human brain following trauma or with astrocytomas. We investigated its expression patterns by immunohistochemistry. We found that 5‐LOX is normally expressed in neurons and glial cells. In neurons, it was expressed in two patterns: in the cytosol and nucleus or only in the cytosol. In traumatic brain injury, 5‐LOX expression increased in glial cells and neutrophils. Double‐labeling immunohistochemistry showed that part of the 5‐LOX‐positive glial cells were GFAP positive. No 5‐LOX expression was found in brain microvessel endothelia, except in the regenerated endothelia of a patient 8 days following brain trauma. Furthermore, 5‐LOX expression increased and showed a granular pattern in high‐grade (grade III/IV) astrocytoma. These results indicate that 5‐LOX has multiple expression patterns, and can be induced by brain injury, which implies that 5‐LOX might have pathophysiological roles in the human brain.